Literature DB >> 17706402

Challenges in Brucella bacteraemia.

Georgios Pappas1, Photini Papadimitriou.   

Abstract

Brucella possesses unique historical, epidemiological, phylogenetic and pathogenetic characteristics that constantly reinforce the pathogen's place at the epicentre of scientific interest. One such unique characteristic is the significance of bacteraemia in the course of the disease. Bacteraemia in brucellosis may be periodically present, of limited practical diagnostic importance, and of doubtful significance as an index of bacteriological cure. On the other hand, recognition of bacteraemia augments prognosis, typing and biotyping (and thus further research). Recent advances in molecular diagnosis with the help of real time polymerase chain reaction (rtPCR) have shown that bacteraemia in brucellosis may persist, at culture non-detectable levels, for protracted periods even after apparent clinical cure. This raises important issues for future research, implying that the pathogen may actually be non-eradicable.

Entities:  

Mesh:

Year:  2007        PMID: 17706402     DOI: 10.1016/j.ijantimicag.2007.06.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  Biochemical Characterization of WbkC, an N-Formyltransferase from Brucella melitensis.

Authors:  Alexander S Riegert; Daniel P Chantigian; James B Thoden; Peter A Tipton; Hazel M Holden
Journal:  Biochemistry       Date:  2017-07-05       Impact factor: 3.162

2.  Bacteremic and nonbacteremic brucellosis: clinical and laboratory observations.

Authors:  A Kadanali; K Ozden; U Altoparlak; A Erturk; M Parlak
Journal:  Infection       Date:  2009-01-12       Impact factor: 3.553

Review 3.  Laboratory Diagnosis of Human Brucellosis.

Authors:  Pablo Yagupsky; Pilar Morata; Juan D Colmenero
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

4.  Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL.

Authors:  Dola Sengupta; Alicia Koblansky; Jennifer Gaines; Tim Brown; A Phillip West; Dekai Zhang; Tak Nishikawa; Sung-Gyoo Park; R Martin Roop; Sankar Ghosh
Journal:  J Immunol       Date:  2009-12-14       Impact factor: 5.422

5.  Establishment of systemic Brucella melitensis infection through the digestive tract requires urease, the type IV secretion system, and lipopolysaccharide O antigen.

Authors:  Tatiane A Paixão; Christelle M Roux; Andreas B den Hartigh; Sumathi Sankaran-Walters; Satya Dandekar; Renato L Santos; Renée M Tsolis
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

6.  Development and characterization of mouse models of infection with aerosolized Brucella melitensis and Brucella suis.

Authors:  Sophie J Smither; Stuart D Perkins; Carwyn Davies; Anthony J Stagg; Michelle Nelson; Helen S Atkins
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

7.  Brucella melitensis invades murine erythrocytes during infection.

Authors:  Marie-Alice Vitry; Delphine Hanot Mambres; Michaël Deghelt; Katrin Hack; Arnaud Machelart; Frédéric Lhomme; Jean-Marie Vanderwinden; Marjorie Vermeersch; Carl De Trez; David Pérez-Morga; Jean-Jacques Letesson; Eric Muraille
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

8.  Human Brucellosis and Adverse Pregnancy Outcomes.

Authors:  Angela M Arenas-Gamboa; Carlos A Rossetti; Sankar P Chaki; Daniel G Garcia-Gonzalez; Leslie G Adams; Thomas A Ficht
Journal:  Curr Trop Med Rep       Date:  2016-10-01

9.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06

10.  Epidemiological, Clinical and Laboratory Characteristics of Patients with Brucella Infection in Anhui Province, China.

Authors:  Cuixiao Shi; Lianzi Wang; Dongmei Lv; Gang Wang; Hylemariam Mihiretie Mengist; Tengchuan Jin; Bo Wang; Ying Huang; Yajuan Li; Yuanhong Xu
Journal:  Infect Drug Resist       Date:  2021-07-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.